, Volume 29, Issue 8, pp 228-231

Manage non-alcoholic fatty liver disease using lifestyle interventions, as evidence for the use of pharmacological options is limited

  • show all 0 hide

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Nonalcoholic fatty liver disease (NAFLD) is commonly associated with components of the metabolic syndrome. Disorders range from simple hepatic steatosis to nonalcoholic steatohepatitis, which has potentially severe outcomes. The aim of treatment of NAFLD is to reverse obesity-associated lipotoxicity and insulin resistance via lifestyle interventions. There is growing evidence for the use of various pharmacological agents in the treatment of this condition.